英文别名 |
GSK3145095;B4D3WPS7JY;BCP31015;s8845;FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1;(S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide;(S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl);GSK-3145095; GSK 3145095;GSK-3145095;DA-77476;CS-0094287;compound 6 [PMID: 31223438];AT16390;5-benzyl-N-[(3S)-7,9-difluoro-2-oxo-1,3,4,5-tetrahydro-1-benzazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide;CHEMBL4452233;UNII-B4D3WPS7JY;BDBM50502339;GSK3145095?;MS-26701;1622849-43-7;XPC84943;SCHEMBL25798915;AC-36366;HY-111946;SCHEMBL25294190;5-benzyl-N-[(3S)-7,9-difluoro-2-oxo-1,3,4,5-tetrahydro-1-benzazepin-3-yl]-2H-1,2,4-triazole-3-carboxamide;SCHEMBL17312826;GTPL12245;EX-A3069;RIPK1 inhibitor GS3145095;AKOS040741817 |